Cognition Therapeutics Advances with CT1812 in Dementia Study

Cognition Therapeutics, Inc. ((CGTX)) announced an update on their ongoing clinical study.

Study Overview: Cognition Therapeutics, Inc. has initiated an Expanded Access Program for CT1812 (Zervimesine), officially titled A Single-arm, Open-label, Expanded Access Program to Provide 100 mg CT1812 (Zervimesine) and to Collect Long-term Safety and Efficacy Data in Participants With Mild-to-moderate Dementia With Lewy Bodies (DLB). The study aims to assess the long-term safety and efficacy of CT1812 in individuals with mild-to-moderate DLB, a significant step in addressing this challenging neurodegenerative condition.

Intervention/Treatment: The intervention being tested is a drug named Zervimesine (CT1812). It is designed to be administered once daily for 12 months to adults aged 50 to 86 diagnosed with mild to moderate DLB, focusing on evaluating its long-term safety and tolerability.

Study Design: This study is a single-arm, open-label, expanded access program. Participants will be screened and enrolled based on specific inclusion criteria. The primary purpose is to provide access to CT1812 and collect safety data over a 360-day treatment period, followed by a follow-up visit.

Study Timeline: The study was first submitted on April 29, 2025, with the latest update submitted on June 27, 2025. These dates mark the initial and most recent steps in the study’s progression, indicating its ongoing status and recent developments.

Market Implications: This update could positively influence Cognition Therapeutics’ stock performance by demonstrating progress in addressing DLB, a condition with limited treatment options. Investors might view this as a promising development, potentially boosting confidence in the company’s pipeline. Competitors in the neurodegenerative treatment space will likely monitor these advancements closely.

The study is ongoing, with further details available on the ClinicalTrials portal.